Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY).
Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, Tane K, Samejima J, Taki T, Hayashi T, Matsubayashi J, Ishii G, Nishikawa H, Ikeda N, Tsuboi M.
Aokage K, et al. Among authors: shimada y.
Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-1561. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39453771